PHARMACEUTICAL EXECUTIVE NEWSLETTER

In this ISSUE

Eight Characteristics of Blockbuster Teams

The EU's Trade Agreement with Canada in the Balance

Emerging Pharma Leaders 2016: Lessons from the Front Bench

Top Story

Major Changes Ahead for Drug User Fees

PDUFA VI to enhance FDA staffing, revise fees and expand evidence for drug development
... /Read more/

Read this Front & Center article to see how your Hub can be a Secret Weapon to improve Outcomes

Learn more

Event

ISPOR Task Force Grapples with Value Questions

ISPOR's Value Assessment Stakeholder Conference showed its Special Task Force still reaching for clarification around the subject, writes Ansis Helmanis
... /Read more/

Achieving Success in the Biosimilar Market
Live Webinar: Wednesday, October 19 at 2 PM EDT

Regulatory

NIH, FDA Seek Broader Disclosure of Clinical Trial Results

The campaign to achieve greater transparency in clinical research activity regulated or funded by the federal government is moving forward after months of debate, writes Jill Wechsler
... /Read more/

Supporting internal and external decision-making through effective MSL activities
Live Webinar: Tuesday 18th October, 11:00am EDT

Special Feature

Pharm Exec's Emerging Pharma Leaders 2016

Pharm Exec's 9th annual list of rising industry leaders illustrates how the deployment of essential human capital has changed in line with a business model that is no longer static and predictable–or complacent
... /Read more/

Technology can't replace people- why Patient Support Programs need a personal approach
Live Webcast: Thursday, September 29 at 8:00 EDT

Calendar

/ October 5: Drug, Chemical & Associated Technology Association (DCAT) After the Show /

Barcelona, Spain

/ October 27–28: MedComm 2016 /

San Francisco, CA

/ December 13–14: Life Sciences Trade and Channel Strategies /

Philadelphia, PA

/ February 08–09, 2017: Speaker Programs 2017 /

Philadelphia, PA

Optimizing real-world evidence programs to generate value
Tailored approaches for emerging biopharma
On Demand

Learn more

Industry update

//UniQure N.V. (Lexington, MA and Amsterdam, The Netherlands) has accepted the resignation of Daniel Soland as Chief Executive Officer and an executive member of the Board.//Endo International plc (Dublin, Ireland) announced that its Board of Directors has named Paul V. Campanelli President and Chief Executive Officer. //Enumeral Biomedical Holdings (Cambridge, MA) appointed Wael Fayad as Chairman, President, and Chief Executive Officer.//

Breaking the Circle of Distrust with a Radical PLC Pricing Model
On Demand

Learn more

advertise with us / print subscribe / digital subscribe / visit pharmexec.com